LivaNova
About LivaNova
LivaNova is a London-headquartered medical-technology company focused on cardiovascular and neuromodulation devices.
Leadership Team
Leadership as listed on livanova.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on livanova.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Essenz Perfusion System
Perfusion system used in cardiopulmonary bypass procedures.
Source: livanova.comVNS Therapy for Epilepsy
Vagus nerve stimulation therapy for drug-resistant epilepsy.
Source: livanova.comVNS Therapy for Depression
Vagus nerve stimulation therapy for difficult-to-treat depression.
Source: livanova.comObstructive Sleep Apnea
Business area developing therapy for obstructive sleep apnea.
Source: livanova.comPipeline & Regulatory Record
What public registers list for LivaNova: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 10 Oct 2026.
Clinical trials 2 in our ClinicalTrials.gov registers
| Study | Phase | Status |
|---|---|---|
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression NCT03887715 · Treatment Resistant Depression |
Not applicable | Recruiting |
| A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression. NCT03320304 · Treatment Resistant Depression |
Observational | Recruiting |
Group (LivaNova): founded 2015, headquarters London, website livanova.com. Wikidata Q21592516 · Wikipedia. From Wikidata (CC0), matched by the group's Legal Entity Identifier.
How this is matched: register records are linked to this page by the organisation name they carry, here LivaNova. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports LivaNova PLC files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $1.39bn | $186m | 13.4% | −$242m | 10-K 2026 |
| Dec 2024 | $1.25bn | $183m | 14.6% | $63.2m | 10-K 2026 |
| Dec 2023 | $1.15bn | $194m | 16.8% | $17.5m | 10-K 2026 |
| Dec 2022 | $1.02bn | $156m | 15.2% | −$86.2m | 10-K 2025 |
| Dec 2021 | $1.04bn | $183m | 17.7% | −$136m | 10-K 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.